본문 바로가기
KERD
논문KCI 등재

Anhedonia and Depressive Disorders

Alessandro Serretti
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2023.08|Clinical Psychopharmacology and Neuroscience|제21권 제3호|pp. 401-409|DOI 10.9758/cpn.23.1086

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

Major depressive disorderAntidepressants.PsychopharmacologyAnhedonia

초록

Anhedonia is a core symptom of depression and of several psychiatric disorders. Anhedonia has however expanded from its original definition to encompass a spectrum of reward processing deficits that received much interest in the last decades. It is a relevant risk factor for possible suicidal behaviors, and that it may operate as an independent risk factor for suicidality apart from the episode severity. Anhedonia has also been linked to inflammation with a possible reciprocal deleterious effect on depression. Its neurophysiological bases mainly include alterations in striatal and prefrontal areas, with dopamine being the most involved neurotransmitter. Anhedonia is thought to have a significant genetic component and polygenic risk scores are a possible tool for predicting an individual’s risk for developing anhedonia. Traditional antidepressants, such as selective serotonin reuptake inhibitors, showed a limited benefit on anhedonia, also considering their potential pro-anhedonic effect in some subjects. Other treatments may be more effective in treating anhedonia, such as agomelatine, vortioxetine, ketamine and transcranial magnetic stimulation. Psychotherapy is also widely supported, with cognitive-behavioral therapy and behavioral activation both showing benefit. In conclusion, a large body of evidence suggests that anhedonia is, at least partially, independent from depression, therefore it needs careful assessment and targeted treatment.

Abstract

Anhedonia is a core symptom of depression and of several psychiatric disorders. Anhedonia has however expanded from its original definition to encompass a spectrum of reward processing deficits that received much interest in the last decades. It is a relevant risk factor for possible suicidal behaviors, and that it may operate as an independent risk factor for suicidality apart from the episode severity. Anhedonia has also been linked to inflammation with a possible reciprocal deleterious effect on depression. Its neurophysiological bases mainly include alterations in striatal and prefrontal areas, with dopamine being the most involved neurotransmitter. Anhedonia is thought to have a significant genetic component and polygenic risk scores are a possible tool for predicting an individual’s risk for developing anhedonia. Traditional antidepressants, such as selective serotonin reuptake inhibitors, showed a limited benefit on anhedonia, also considering their potential pro-anhedonic effect in some subjects. Other treatments may be more effective in treating anhedonia, such as agomelatine, vortioxetine, ketamine and transcranial magnetic stimulation. Psychotherapy is also widely supported, with cognitive-behavioral therapy and behavioral activation both showing benefit. In conclusion, a large body of evidence suggests that anhedonia is, at least partially, independent from depression, therefore it needs careful assessment and targeted treatment.

참고문헌 (101)

  1. Lewis WB, "A text-book of mental diseases: With special reference to the pathological aspects of insanity", pp.552~ (1889), Griffin
  2. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (1980), American Psychiatric Association
  3. Carlson GA, "Phenomenology of major depression from childhood through adulthood : Analysis of three studies", Am J Psychiatry, 145, pp.1222~1225 (1988)
  4. Rizvi SJ, "Assessing anhedonia in depression : Potentials and pitfalls", Neurosci Biobehav Rev, 65, pp.21~35 (2016)
  5. Wang S, "Anhedonia as a central factor in depression : Neural mechanisms revealed from preclinical to clinical evidence", Prog Neuropsychopharmacol Biol Psychiatry, 110, pp.110289~ (2021)
  6. Treadway MT, "Reconsidering anhedonia in depression : Lessons from translational neuroscience", Neurosci Biobehav Rev, 35, pp.537~555 (2011)
  7. Whitton AE, "Anhedonia in depression and bipolar disorder", Curr Top Behav Neurosci, 58, pp.111~127 (2022)
  8. Der-Avakian A, "The neurobiology of anhedonia and other reward-related deficits", Trends Neurosci, 35, pp.68~77 (2012)
  9. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5-TR", pp.1050~ (2022), American Psychiatric Association Publishing
  10. Pizzagalli DA, "Anhedonia: Preclinical, translational, and clinical integration", pp.3~515 (2022), Springer Nature
  11. Watson CG, "Toward an operational definition of anhedonia", Psychol Rep, 26, pp.371~376 (1970)
  12. Phillips AG, "Anticipation : An essential feature of anhedonia", Curr Top Behav Neurosci, 58, pp.305~323 (2022)
  13. Kieslich K, "Pleasure, reward value, prediction error and anhedonia", Curr Top Behav Neurosci, 58, pp.281~304 (2022)
  14. Thomsen KR, "Measuring anhedonia : Impaired ability to pursue, experience, and learn about reward", Front Psychol, 6, pp.1409~ (2015)
  15. Insel T, "Research domain criteria(RDoC) : Toward a new classification framework for research on mental disorders", Am J Psychiatry, 167, pp.748~751 (2010)
  16. Barbano MF, "Opioids for hedonic experience and dopamine to get ready for it", Psychopharmacology(Berl), 191, pp.497~506 (2007)
  17. Gandhi A, "A transdiagnostic meta-analysis of physical and social Anhedonia in major depressive disorder and schizophrenia spectrum disorders", Psychiatry Res, 309, pp.114379~ (2022)
  18. Winer ES, "Conceptualizing anhedonias and implications for depression treatments", Psychol Res Behav Manag, 12, pp.325~335 (2019)
  19. Cao B, "Pharmacological interventions targeting anhedonia in patients with major depressive disorder : A systematic review", Prog Neuropsychopharmacol Biol Psychiatry, 92, pp.109~117 (2019)
  20. Fletcher K, "Anhedonia in melancholic and non-melancholic depressive disorders", J Affect Disord, 184, pp.81~88 (2015)
  21. Trøstheim M, "Assessment of anhedonia in adults with and without mental illness : A systematic review and meta-analysis", JAMA Netw Open, 3, pp.e2013233~ (2020)
  22. Di Nicola M, "Reduced hedonic capacity in euthymic bipolar subjects : A trait-like feature?", J Affect Disord, 147, pp.446~450 (2013)
  23. Dodell-Feder D, "Epidemiological dimensions of social anhedonia", Clin Psychol Sci, 6, pp.735~743 (2018)
  24. Gard DE, "Anhedonia in schizophrenia : Distinctions between anticipatory and consummatory pleasure", Schizophr Res, 93, pp.253~260 (2007)
  25. Snaith RP, "A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale", Br J Psychiatry, 167, pp.99~103 (1995)
  26. Ciaramelli E, "The role of ventromedial prefrontal cortex in reward valuation and future thinking during intertemporal choice", Elife, 10, pp.e67387~ (2021)
  27. Staudinger MR, "Dorsolateral prefrontal cortex modulates striatal reward encoding during reappraisal of reward anticipation", Cereb Cortex, 21, pp.2578~2588 (2011)
  28. Borsini A, "Characterizing anhedonia : A systematic review of neuroimaging across the subtypes of reward processing deficits in depression", Cogn Affect Behav Neurosci, 20, pp.816~841 (2020)
  29. Treadway MT, "The neurobiology of motivational deficits in depression--an update on candidate pathomechanisms", Curr Top Behav Neurosci, 27, pp.337~355 (2016)
  30. Tejeda HA, "Dynorphin", kappa-opioid receptor control of dopamine dynamics : Implications for negative affective states and psychiatric disorders, 2019, pp.1713, 91~101
  31. Morales M, "Ventral tegmental area : Cellular heterogeneity, connectivity and behaviour", Nat Rev Neurosci, 18, pp.73~85 (2017)
  32. Bondy E, "Understanding anhedonia from a genomic perspective", Curr Top Behav Neurosci, 58, pp.61~79 (2022)
  33. Berenbaum H, "Hedonic capacity in schizophrenics and their twins", Psychol Med, 20, pp.367~374 (1990)
  34. Berenbaum H, "Familial resemblance of schizotypic traits", Psychol Med, 23, pp.327~333 (1993)
  35. Clementz BA, "Psychometric detection of schizotypy : Perceptual aberration and physical anhedonia in relatives of schizophrenics", J Abnorm Psychol, 100, pp.607~612 (1991)
  36. Franke P, "Cognitive functioning and anhedonia in subjects at risk for schizophrenia", Schizophr Res, 10, pp.77~84 (1993)
  37. Hay DA, "Phenotypic and genetic analyses of a short measure of psychosis-proneness in a large-scale Australian twin study", Twin Res, 4, pp.30~40 (2001)
  38. Kendler KS, "The structure of schizotypy : A pilot multitrait twin study", Psychiatry Res, 36, pp.19~36 (1991)
  39. Ward J, "Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure", Transl Psychiatry, 9, pp.327~ (2019)
  40. Zhu X, "Phenotypic and genetic associations between anhedonia and brain structure in UK Biobank", Transl Psychiatry, 11, pp.395~ (2021)
  41. Bang M, "Reduced DNA methylation of the oxytocin receptor gene is associated with anhedonia-asociality in women with recent-onset schizophrenia and ultra-high risk for psychosis", Schizophr Bull, 45, pp.1279~1290 (2019)
  42. Vinckier F, "Anhedonia predicts poor psychosocial functioning : Results from a large cohort of patients treated for major depressive disorder by general practitioners", Eur Psychiatry, 44, pp.1~8 (2017)
  43. Gabbay V, "Anhedonia, but not irritability, is associated with illness severity outcomes in adolescent major depression", J Child Adolesc Psychopharmacol, 25, pp.194~200 (2015)
  44. Spijker J, "Determinants of poor 1-year outcome of DSM-III-R major depression in the general population : Results of the Netherlands Mental Health Survey and Incidence Study(NEMESIS)", Acta Psychiatr Scand, 103, pp.122~130 (2001)
  45. Auerbach RP, "Anhedonia and suicide", Curr Top Behav Neurosci, 58, pp.443~464 (2022)
  46. Bonanni L, "Can anhedonia be considered a suicide risk factor? A review of the literature", Medicina (Kaunas), 55, pp.458~ (2019)
  47. Pompili M, "Persistent suicidal ideation in major depressive disorder patients : Still in need of empathic understanding", Int Clin Psychopharmacol, 37, pp.279~280 (2022)
  48. Olgiati P, "Persistence of suicidal ideation within acute phase treatment of major depressive disorder : Analysis of clinical predictors", Int Clin Psychopharmacol, 37, pp.193~200 (2022)
  49. Olgiati P, "Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder", Int Clin Psychopharmacol (2023)[DOI]
  50. Ballard ED, "Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials", J Affect Disord, 218, pp.195~200 (2017)
  51. Ducasse D, "Association between anhedonia and suicidal events in patients with mood disorders : A 3-year prospective study", Depress Anxiety, 38, pp.17~27 (2021)
  52. Ducasse D, "Anhedonia is associated with suicidal ideation independently of depression : A meta-analysis", Depress Anxiety, 35, pp.382~392 (2018)
  53. Fawcett J, "Time-related predictors of suicide in major affective disorder", Am J Psychiatry, 147, pp.1189~1194 (1990)
  54. Sagud M, "Physical and social anhedonia are associated with suicidality in major depression, but not in schizophrenia", Suicide Life Threat Behav, 51, pp.446~454 (2021)
  55. Felger JC, "Inflammation effects on motivation and motor activity : Role of dopamine", Neuropsychopharmacology, 42, pp.216~241 (2017)
  56. Felger JC, "Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression", Mol Psychiatry, 21, pp.1358~1365 (2016)
  57. Haroon E, "Conceptual convergence : Increased inflammation is associated with increased basal ganglia glutamate in patients with major depression", Mol Psychiatry, 21, pp.1351~1357 (2016)
  58. Lee Y, "Anti-cytokine agents for anhedonia : Targeting inflammation and the immune system to treat dimensional disturbances in depression", Ther Adv Psychopharmacol, 8, pp.337~348 (2018)
  59. Vichaya EG, "Inflammation-induced motivational changes : Perspective gained by evaluating positive and negative valence systems", Curr Opin Behav Sci, 22, pp.90~95 (2018)
  60. Raison CL, "A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression : The role of baseline inflammatory biomarkers", JAMA Psychiatry, 70, pp.31~41 (2013)
  61. Benedetti F, "Antidepressant psychopharmacology : Is inflammation a future target?", Int Clin Psychopharmacol, 37, pp.79~81 (2022)
  62. Ho N, "Anhedonia : A concept analysis", Arch Psychiatr Nurs, 27, pp.121~129 (2013)
  63. Buckner JD, "Implications of the DSM’s emphasis on sadness and anhedonia in major depressive disorder", Psychiatry Res, 159, pp.25~30 (2008)
  64. Harmer CJ, "How do antidepressants work? New perspectives for refining future treatment approaches", Lancet Psychiatry, 4, pp.409~418 (2017)
  65. Serretti A, "Antidepressants in healthy subjects : What are the psychotropic", psychological effects?, 2010, pp.20, 433~453
  66. Tomarken AJ, "Assessing the effects of bupropion SR on mood dimensions of depression", J Affect Disord, 78, pp.235~241 (2004)
  67. Majeed A, "Efficacy of dextromethorphan for the treatment of depression : A systematic review of preclinical and clinical trials", Expert Opin Emerg Drugs, 26, pp.63~74 (2021)
  68. Cryan JF, "Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat", Psychopharmacology(Berl), 168, pp.347~358 (2003)
  69. Paterson NE, "Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell", Eur J Neurosci, 25, pp.3099~3108 (2007)
  70. Walsh AEL, "A dissociation of the acute effects of bupropion on positive emotional processing and reward processing in healthy volunteers", Front Psychiatry, 9, pp.482~ (2018)
  71. Lemke MR, "Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease", J Neurol Sci, 248, pp.266~270 (2006)
  72. Farabaugh A, "Similar changes in cognitions following cognitive-behavioral therapy or escitalopram for major depressive disorder : Implications for mechanisms of change", Ann Clin Psychiatry, 27, pp.118~126 (2015)
  73. Corruble E, "Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder : A 24-wk randomized, controlled, double-blind trial", Int J Neuropsychopharmacol, 16, pp.2219~2234 (2013)
  74. Boyer P, "Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression", J Clin Pharm Ther, 25, pp.363~371 (2000)
  75. Light SN, "Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder", Biol Psychiatry, 70, pp.962~968 (2011)
  76. Martinotti G, "Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder : A pilot study", J Clin Psychopharmacol, 32, pp.487~491 (2012)
  77. Di Giannantonio M, "Major depressive disorder, anhedonia and agomelatine : An open-label study", J Biol Regul Homeost Agents, 25, pp.109~114 (2011)
  78. Martinotti G, "Agomelatine increases BDNF serum levels in depressed patients in correlation with the improvement of depressive symptoms", Int J Neuropsychopharmacol, 19, pp.pyw003~ (2016)
  79. Gargoloff PD, "Effectiveness of agomelatine on anhedonia in depressed patients : An outpatient, open-label, real-world study", Hum Psychopharmacol, 31, pp.412~418 (2016)
  80. De Berardis D, "Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder : An exploratory study in"real-world, "everyday clinical practice", CNS Spectr, 22, pp.342~347 (2017)
  81. di Giannantonio M, "Agomelatine effectiveness, tolerability, and impact on anhedonia in major depression : A pooled analysis", J Clin Psychopharmacol, 39, pp.288~290 (2019)
  82. McIntyre RS, "Efficacy of vortioxetine on anhedonia : Results from a pooled analysis of shortterm studies in patients with major depressive disorder", Neuropsychiatr Dis Treat, 17, pp.575~585 (2021)
  83. Mattingly GW, "Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder : Findings from two open-label studies", Curr Med Res Opin, 39, pp.613~619 (2023)
  84. Watanabe K, "Therapeutic potential of vortioxetine for anhedonia-like symptoms in depression : A post hoc analysis of data from a clinical trial conducted in Japan", Neuropsychiatr Dis Treat, 18, pp.363~373 (2022)
  85. Cao B, "The efficacy of vortioxetine on anhedonia in patients with major depressive disorder", Front Psychiatry, 10, pp.17~ (2019)
  86. Tan SN, "Vortioxetine improves cognition in mild cognitive impairment", Int Clin Psychopharmacol, 36, pp.279~287 (2021)
  87. Tham JCW, "Repeated subcutaneous racemic ketamine in treatment-resistant depression : Case series", Int Clin Psychopharmacol, 37, pp.206~214 (2022)
  88. Bahji A, "Comparative efficacy of racemic ketamine and esketamine for depression : A systematic review and meta-analysis", J Affect Disord, 278, pp.542~555 (2021)
  89. Zanos P, "Mechanisms of ketamine action as an antidepressant", Mol Psychiatry, 23, pp.801~811 (2018)
  90. Lally N, "Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression", Transl Psychiatry, 4, pp.e469~ (2014)
  91. Goodwin GM, "Single-dose psilocybin for a treatmentresistant episode of major depression", N Engl J Med, 387, pp.1637~1648 (2022)
  92. Carhart-Harris RL, "Psilocybin with psychological support for treatment-resistant depression : An open-label feasibility study", Lancet Psychiatry, 3, pp.619~627 (2016)
  93. Rizvi SJ, "Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder : Effects of apathy", anhedonia and fatigue, 2014, pp.34, 755~759
  94. Pettorruso M, "Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex may improve symptoms of anhedonia in individuals with cocaine use disorder : A pilot study", Brain Stimul, 11, pp.1195~1197 (2018)
  95. Light SN, "Measuring change in anhedonia using the"Happy Faces"task pre-to post-repetitive transcranial magnetic stimulation(rTMS)treatment to left dorsolateral prefrontal cortex in Major Depressive Disorder(MDD) : Relation to empathic happiness", Transl Psychiatry, 9, pp.217~ (2019)
  96. Spano MC, "Anhedonia across borders : Transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes", CNS Neurosci Ther, 25, pp.1229~1236 (2019)
  97. Wang X, "Therapeutic efficacy of connectivity-directed transcranial magnetic stimulation on anticipatory anhedonia", Depress Anxiety, 38, pp.972~984 (2021)
  98. Fukuda AM, "Effects of transcranial magnetic stimulation on anhedonia in treatment resistant major depressive disorder", Brain Behav, 11, pp.e2329~ (2021)
  99. van Bronswijk S, "Effectiveness of psychotherapy for treatment-resistant depression : A meta-analysis and meta-regression", Psychol Med, 49, pp.366~379 (2019)
  100. Alsayednasser B, "How well do cognitive behavioural therapy and behavioural activation for depression repair anhedonia? A secondary analysis of the COBRA randomized controlled trial", Behav Res Ther, 159, pp.104185~ (2022)
  101. Serretti A, "Advances in the treatment of depression", Int Clin Psychopharmacol, 37, pp.183~184 (2022)

관련 논문AI추천

Behavioral Activation and Brain Network Changes in DepressionKyu-Man Han, Minjee Jung대한신경과학회 · Journal of Clinical Neurology2024 · 제20권 제4호Understanding the Complex of Suicide in Depression: from Research to ClinicsAlessandro Valchera, Carmine Tomasetti, Domenico De Berardis, Federica Vellante, Gianluca Serafini, Giovanni Martinotti, Laura Orsolini, Marco Alessandrini, Massimo Di Giannantonio, Maurizio Pompili, Michele Fornaro, Raffaella La Rovere, Roberto Latini, Sabatino Trotta, Silvia Fraticelli, Umberto Volpe대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제3호Biomarkers of Major Depressive Disorder: Knowing is Half the BattleAkriti Dangol, Govind Arora, Ravinder Singh, Sahil Malik, Sanjay Goyal대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제1호Depression and Cognition곽용태, 구민성, 양영순대한치매학회 · Dementia and Neurocognitive Disorders(대한치매학회지)2016 · 제15권 제4호The Role of Glutamate Underlying Treatment-resistant DepressionJa Wook Koo, Jeongseop Kim, Seung-Hwan Lee, Tae-Eun Kim대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제3호Neuroinflammation, Gut-Brain Axis and DepressionAlper Evrensel, Barıs¸ Önen Ünsalver, Mehmet Emin Ceylan대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제1호

이 간행물의 다른 논문 (19건)

The Impact of COVID-19 on Psychiatric Health in the Korean Population배치운, Hyun Kook Lim, Won-Seok Choi, Young Sup Woo, Sheng Min Wang, Sung-Hwan Kim, 박원명pp. 410-418The Link between Suicidality and Electroencephalography Asymmetry: A Systematic Review and Meta-analysisLaine B. Butler, Kate B. Noonerpp. 419-428The Role of Glutamate Underlying Treatment-resistant DepressionTae-Eun Kim, Seung-Hwan Lee, Ja Wook Koo, Jeongseop Kimpp. 429-446Development of a Guideline for Antipsychotic-induced Hyperprolactinemia in Korea Using the ADAPTE Process전홍준, 전덕인, 김선미, 정종현, Jeongwan Hong, Seung-Ho Jang, Hye Ri Kim, Won Sub Kangpp. 447-456Does Post-traumatic Stress Disorder Impact Treatment Outcomes within a Randomised Controlled Trial of Mitochondrial Agents for Bipolar Depression?MIchael Berk, Samantha E. Russell, Anna L. Wrobel, Olivia M. Dean, Seetal Dodd, Chee H. Ng, Gin S. Malhi, Alyna Turner, Mohammadreza Mohebbi, Melanie M. Ashton, Sue Cottonpp. 457-465
원문 보기